2025-12-15T11:00:30-06:00 2025-01-31 010494526 Baker Newman & Noyes PO Box 507 Portland ME 04112 990 2024-02-01 264510094 TargetCancer Foundation Inc TARG 6177654881 955 Massachusetts Avenue 343 Cambridge MA 02139 James Palma Chief Executive Officer 6177654881 2025-12-12 1 0 Connor Smart P02285543 2078792100 2025-12-12 2024 2025-03-06 01:10:19Z James Palma 955 Massachusetts Avenue 343 Cambridge MA 02139 1372762 0 X www.targetcancer.org X 2009 MA Support for research into the causes and treatments of rare cancers. 11 9 4 30 0 0 674113 1308131 0 0 2338 29761 0 -76283 676451 1261609 25000 0 0 0 334776 402014 0 0 108005 437898 437034 797674 839048 -121223 422561 523908 1016178 0 0 523908 1016178 X TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients. 0 0 508441 0 0 The specific purposes of the Organization are to raise awareness of and support for research into rare cancers, and to directly support patients and families facing rare cancers. This was accomplished in the fiscal year through the ongoing operation of a rare cancer precision medicine clinical trial, and through other programs. In 2020, TargetCancer Foundation launched a rare cancer precision medicine clinical trial called TCF-001 TRACK (Target Rare Cancer Knowledge). TRACK is a 400-patient clinical trial studying genomics and precision medicine in rare cancers, providing patients with critical personalized genomic data about their cancer and treatment recommendations from a panel of field leaders, and also generating rare cancer research data. TRACK is developed, sponsored and managed by TargetCancer Foundation, and is currently over halfway through its enrollment of patients with rare cancers and cancer of unknown primary.In 2024, TargetCancer Foundation held a major scientific meeting- the Think Tank on Advancing Precision Medicine in Rare Cancers. This unique, innovative meeting unites key stakeholders including clinicians, researchers, government, industry, and patients and advocates. This meeting is specifically designed to promote collaboration, information-sharing and idea generation in an effort to define research priorities, foster new collaborative efforts across institutions, and ultimately propel the field forward.In 2024, TargetCancer Foundation launched its Patient Outreach, Education and Support Program, which provides online and downloadable educational resources designed for patients navigating a rare cancer diagnosis. Theis includes resources such as What is a Rare Cancer, Initial Steps for Navigating a Rare Cancer Diagnosis, Clinical Trials, and Biomarker Testing. In addition, this program includes an educational webinar series intended for patients and caregivers. 508441 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 16 0 1 4 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 11 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 MA X James Palma 6177654881 955 Massachusetts Avenue 343 Cambridge MA 02139 Jerry Alderman Director 1.00 X 0 0 0 Jennifer Levin Carter MD Director 1.00 X 0 0 0 CJ Chapman Director 1.00 X 0 0 0 Samuel Davenport Director 1.00 X 0 0 0 Janet Fine MS Director 1.00 X 0 0 0 Mary Pat Lancelotta Director 1.00 X 0 0 0 Kristen Schuler Scammon Director 1.00 X 0 0 0 Andrea Sullivan Director 1.00 X 0 0 0 Kristen Palma President/Director 40.00 X X 55397 0 11933 Colin Carey Treasurer/Director 1.00 X X 0 0 0 James M Palma Chief Executive Officer 50.00 X X 168555 0 5502 223952 0 17435 1 0 1 0 0 478824 829307 34000 1308131 29761 29761 34870 478824 111153 -76283 -76283 1261609 0 0 -46522 X 243322 145993 60830 36499 128132 76880 32033 19219 3415 2049 854 512 25 15 6 4 27120 16272 6780 4068 13678 13678 212871 92025 91096 29750 628 628 8042 4492 1775 1775 36563 20421 8071 8071 22981 12835 5073 5073 4461 2491 985 985 1831 1023 404 404 3134 1750 692 692 1473 823 325 325 Cancer think tanks 74067 74067 TRACK clinical trials 45845 45845 Patient education 34236 34236 Accrual-to-cash entry -22776 -22776 839048 508441 222602 108005 65499 140737 450174 856620 3150 8235 15671 523908 1016178 0 0 X 523908 974770 41408 523908 1016178 523908 1016178 422561 69709 0 X X 0 1 X 1 0 X 522520 510048 841881 743822 1308131 3926402 522520 510048 841881 743822 1308131 3926402 1108519 2817883 467 463 1819 2338 29761 34848 3961250 0.71140 0.77620 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1266316 4707 4707 1261609 0 1261609 866531 27483 27483 839048 0 839048 Part X, Line 2: The Foundation is qualified under the provisions of Section 501(c)(3) of the Internal Revenue Code and is exempt from federal and state income taxes. Accordingly, there is no provision for income taxes within the financial statements. Tax-exempt organizations could be required to record an obligation for income taxes as the result of a tax position they have historically taken on various tax exposure items including unrelated business income or tax status. Under guidance issued by the Financial Accounting Standards Board (FASB), assets and liabilities are established for uncertain tax positions taken or positions expected to be taken in income tax returns when such positions are judged to not meet the "more-likely-than-not" threshold, based upon the technical merits of the position. Estimated interest and penalties, if applicable, related to uncertain tax positions are included as a component of income tax expense. The Foundation has evaluated the position taken on its filed tax returns. It has not taken, nor does it expect to take, any uncertain tax positions in any income tax return. Part XI, Line 2d - Other Adjustments: Fundraising event expenses 4,707. Part XII, Line 2d - Other Adjustments: Fundraising event expenses 4,707. Net accrual-to-cash expense adjustment 22,776. Gala 331560 296690 34870 34000 31115 31708 790 8833 Marathon 182134 182134 4707 513694 478824 34870 34000 31115 31708 790 13540 111153 -76283 Form 990, Schedule G, Part II, Fundraising Events: During the period covered by this Form 990, the Organization held a fundraising event. At this event the large majority of revenues came in the form of donations, gifts, and sponsorships. In accordance with IRS Form 990 and Schedule G Instructions, contributions and donations received through fundraising events are not included within the reported events' net income on Form 990, Part VIII, Line 8c; or on Form 990, Schedule G, Part II, Line 11. Accordingly, while this Form 990 and Schedule G report a "net loss" from these events of approximately $72,000, this is only because this loss figure does not include the donations received pursuant to these fundraising events and activities. When including the donations and contributions received through the events, the actual net income from the events was a positive gain of over $225,000. X X X 0 0 0 0 0 0 0 1 0 James M Palma Chief Executive Officer 137555 0 31000 0 0 0 5502 0 0 0 174057 0 0 0 Part I, Line 7 From time-to-time the Foundation pays performance-based compensation, which is variable and subject to review by independent individuals consistent with the Foundation's compensation oversight policies. X Auction Prizes 38 34000 Value per book 0 0 0 Form 990, Part VI, Section A, line 2 Kristen Palma, President/Director, and James Palma, Chief Executive Officer, have a family relationship. Form 990, Part VI, Section B, line 11b The original annual Form 990 (along with a copy for them to retain for their records), as prepared by an independent public accounting firm, is submitted to the President, Kristen Palma, for her review and signature prior to filing with the IRS. At that same time, a copy of Form 990 is also provided to the Chief Executive Officer, James Palma, for his review so any comments, questions, or concerns he may have can be raised before the original signed form is filed. Form 990, Part VI, Section B, line 12c In accordance with Articles VI and VII of the Organization's bylaws, annual statements and periodic reviews are conducted to ensure compliance with the conflict of interest policy. Form 990, Part VI, Section B, line 15a Independent members of the board of directors review and approve the annual salary of the Executive Director and all other employees of the organization based on comparable salaries of similarly situated persons performing similar duties of similar size non-profit organizations. Form 990, Part VI, Section C, line 19 The Organization makes its governing documents, conflict of interest policy, and financial statements available to the public upon request. Form 990, Part IX, line 11g Consultancy: Program service expenses 92,025. Management and general expenses 91,096. Fundraising expenses 29,750. Total expenses 212,871. Form 990, Part XII, Line 2c: The Organization's board of directors is charged with oversight of the audit process.